Jaundice induced by streptokinase.
Streptokinase is the mainstream therapy for acute myocardial infarction. A fifty-seven-year-old man with acute MI was admitted to the intensive cardiac care unit and received streptokinase and heparin. At the time of admission, he was not receiving any drugs and denied any previous exposure to a hepatotoxic agent. Five hours later he developed a dramatic hypersensitivity reaction including high fever, pulmonary edema, cyanosis, and convulsions. Within twelve hours, his clinical state was stabilized. After forty-eight hours, he developed jaundice and transaminasemia, which subsided by the eighth day. Only a few reports of overt jaundice are associated with streptokinase.
Gilutz
H
H
Soroka Medical Center, Beer Sheva, Israel.
Cohn
G
G
Battler
A
A
D000925:Anticoagulants / Q000627:therapeutic use; D003490:Cyanosis / Q000139:chemically induced; D004342:Drug Hypersensitivity / Q000209:etiology; D005334:Fever / Q000139:chemically induced; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011654:Pulmonary Edema / Q000139:chemically induced; D012640:Seizures / Q000139:chemically induced; D013300:Streptokinase / Q000009:adverse effects*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D000637:Transaminases / Q000097:blood
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin; D000637:Transaminases; D013300:Streptokinase